GlassScriptPhysician profile
Razia Sami
NPI 1982709382
$1,596.16
in general payments reported to CMS, 2019-2025
18 companies · $565 in 2025
The $565 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $114 · 2023: $656 · 2024: $260 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,481.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $374.67 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $175.00 | 2023 | Korlym |
| Vanda Pharmaceuticals INC. | $173.16 | 2025 | Fanapt |
| Bayer Healthcare Pharmaceuticals INC. | $132.24 | 2023-2024 | |
| Xeris Pharmaceuticals, INC. | $105.73 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Insulet Corporation | $103.27 | 2022-2024 | Omnipod |
| Abbvie INC. | $97.78 | 2023-2024 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $76.91 | 2022-2024 | Farxiga |
| Dexcom, INC. | $74.25 | 2023-2025 | Dexcom G6 Transmitter |
| Organon LLC | $48.50 | 2022 | |
| Lilly USA, LLC | $48.46 | 2025 | Jardiance |
| Exact Sciences Corporation | $44.22 | 2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.01 | 2023-2024 | Xifaxan |
| Abbott Laboratories | $27.73 | 2023 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $26.29 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $22.86 | 2023 | Gardasil 9, M-M-R II, Vaxneuvance |
| Novartis Pharmaceuticals Corporation | $20.69 | 2023 | |
| Axsome Therapeutics, INC. | $13.39 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Razia Sami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.